Analyst Ratings For Pacira BioSciences
6 analysts have shared their evaluations of Pacira BioSciences (NASDAQ:PCRX) during the recent three months, expressing a mix…
A Glimpse Into The Expert Outlook On Pacira BioSciences Through 6 Analysts
Across the recent three months, 6 analysts have shared their insights on Pacira BioSciences (NASDAQ:PCRX), expressing a variety…
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums…
Pacira BioSciences Awarded Brand Pharmaceuticals Agreement With Premier, Inc.; Agreement Allows Premier Members, At Their Discretion, To Take Advantage Of Special Pricing And Terms Pre-negotiated By Premier For EXPAREL
Pacira BioSciences, Inc., (NASDAQ:PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, has been awarded a national group purchasing agreement for Brand
A Glimpse Into The Expert Outlook On Pacira BioSciences Through 7 Analysts
Pacira BioSciences (NASDAQ:PCRX) underwent analysis by 7 analysts in the last quarter, revealing a spectrum of viewpoints from…
Earnings Scheduled For November 2, 2023
Companies Reporting Before The Bell
• AudioCodes (NASDAQ:AUDC) is estimated to report quarterly earnings at $0.18 per share on revenue of $61.52 million.
Earnings Preview: Pacira BioSciences
Pacira BioSciences (NASDAQ:PCRX) is set to give its latest quarterly earnings report on Thursday, 2023-11-02. Here’s what investors…
Analyst Expectations for Pacira BioSciences’s Future
Within the last quarter, Pacira BioSciences (NASDAQ:PCRX) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…
